

# Vitiligo Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/V664D49B9A64EN.html>

Date: May 2024

Pages: 130

Price: US\$ 6,499.00 (Single User License)

ID: V664D49B9A64EN

## Abstracts

The 7 major vitiligo markets reached a value of US\$ 307.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 439.1 Million by 2034, exhibiting a growth rate (CAGR) of 3.3% during 2024-2034.

The vitiligo market has been comprehensively analyzed in IMARC's new report titled "Vitiligo Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Vitiligo refers to a long-term autoimmune condition that causes the skin to lose pigmentation or color in patches. This results when melanocytes, the pigment-producing skin cells, are attacked and destroyed by the body's defense system, leaving the skin milky white. The disease can occur anywhere in the body, but it usually starts on the hands, forearms, face, and feet. Depending on the spread and appearance of skin spots, the condition is majorly classified into nonsegmental, segmental, and mixed vitiligo. Individuals suffering from this ailment may experience loss of skin color, altered color in the retina, premature hair whitening, etc. In addition to the physical symptoms, vitiligo can also have a significant psychological impact, causing embarrassment, anxiety, and low self-esteem. Diagnosing this illness is typically based on the patient's medical history and examination of indications. A healthcare professional may use a Wood's lamp, which emits ultraviolet light, to help distinguish between vitiligo and other skin conditions. Additionally, blood tests may be ordered to check for underlying autoimmune disorders that may be associated with the ailment.

The increasing incidence of autoimmune diseases, including Hashimoto's thyroiditis, scleroderma, psoriasis, etc., and the growing cases of nervous system dysfunction are primarily driving the vitiligo market. Furthermore, the rising prevalence of various associated risk factors, such as severe sunburn, stress, skin trauma, genetic predisposition, etc., is also propelling the market growth. In addition to this, the

escalating utilization of several medications, including topical corticosteroids and calcineurin inhibitors, which can decrease inflammation and the spread of pigmentation loss, is creating a positive outlook for the market. Moreover, the inflating usage of light therapy for patients that works by stimulating specific growth factors to restore the natural skin color is also bolstering the vitiligo market. Apart from this, the emerging popularity of camouflaging cosmetics, tanning products, and skin dye, since they can aid in covering the appearance of redness, depigmentation, and hyperpigmentation related to the ailment, is acting as another significant growth-inducing factor. Additionally, the widespread adoption of Janus kinase inhibitors, which calm down an overactive immune response and help to repigment the skin, is expected to drive the vitiligo market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the vitiligo market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for vitiligo and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the vitiligo market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

## Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the vitiligo market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the vitiligo market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current vitiligo marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

### Key Questions Answered in this Report:

Market Insights

How has the vitiligo market performed so far and how will it perform in the coming years?

What are the market shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the vitiligo market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the vitiligo market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

## Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of vitiligo across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of vitiligo by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of vitiligo by gender across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of vitiligo by type across the seven major markets?

How many patients are diagnosed (?2018-2034?) with vitiligo across the seven major markets?

What is the size of the vitiligo patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of vitiligo?

What will be the growth rate of patients across the seven major markets?

## Vitiligo: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for vitiligo drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the vitiligo market?

What are the key regulatory events related to the vitiligo market?

What is the structure of clinical trial landscape by status related to the vitiligo market?

What is the structure of clinical trial landscape by phase related to the vitiligo market?

What is the structure of clinical trial landscape by route of administration related to the vitiligo market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 VITILIGO - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 VITILIGO - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 VITILIGO - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (?2018-2034?)
  - 7.2.4 Epidemiology by Gender (?2018-2034?)
  - 7.2.5 Epidemiology by Type (?2018-2034?)
  - 7.2.6 Diagnosed Cases (?2018-2034?)
  - 7.2.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (?2018-2034?)
  - 7.3.4 Epidemiology by Gender (?2018-2034?)
  - 7.3.5 Epidemiology by Type (?2018-2034?)
  - 7.3.6 Diagnosed Cases (?2018-2034?)
  - 7.3.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (?2018-2034?)
  - 7.4.4 Epidemiology by Gender (?2018-2034?)
  - 7.4.5 Epidemiology by Type (?2018-2034?)
  - 7.4.6 Diagnosed Cases (?2018-2034?)
  - 7.4.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (?2018-2034?)
  - 7.5.4 Epidemiology by Gender (?2018-2034?)
  - 7.5.5 Epidemiology by Type (?2018-2034?)
  - 7.5.6 Diagnosed Cases (?2018-2034?)
  - 7.5.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (?2018-2034?)
  - 7.6.4 Epidemiology by Gender (?2018-2034?)
  - 7.6.5 Epidemiology by Type (?2018-2034?)
  - 7.6.6 Diagnosed Cases (?2018-2034?)

7.6.7 Patient Pool/Treated Cases (?2018-2034?)

## 7.7 Epidemiology Scenario - Italy

7.7.1 Epidemiology Scenario (2018-2023)

7.7.2 Epidemiology Forecast (2024-2034)

7.7.3 Epidemiology by Age (?2018-2034?)

7.7.4 Epidemiology by Gender (?2018-2034?)

7.7.5 Epidemiology by Type (?2018-2034?)

7.7.6 Diagnosed Cases (?2018-2034?)

7.7.7 Patient Pool/Treated Cases (?2018-2034?)

## 7.8 Epidemiology Scenario - Spain

7.8.1 Epidemiology Scenario (2018-2023)

7.8.2 Epidemiology Forecast (2024-2034)

7.8.3 Epidemiology by Age (?2018-2034?)

7.8.4 Epidemiology by Gender (?2018-2034?)

7.8.5 Epidemiology by Type (?2018-2034?)

7.8.6 Diagnosed Cases (?2018-2034?)

7.8.7 Patient Pool/Treated Cases (?2018-2034?)

## 7.9 Epidemiology Scenario - Japan

7.9.1 Epidemiology Scenario (2018-2023)

7.9.2 Epidemiology Forecast (2024-2034)

7.9.3 Epidemiology by Age (?2018-2034?)

7.9.4 Epidemiology by Gender (?2018-2034?)

7.9.5 Epidemiology by Type (?2018-2034?)

7.9.6 Diagnosed Cases (?2018-2034?)

7.9.7 Patient Pool/Treated Cases (?2018-2034?)

## **8 VITILIGO - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

8.1 Guidelines, Management and Treatment

8.2 Treatment Algorithm

## **9 VITILIGO - UNMET NEEDS**

## **10 VITILIGO - KEY ENDPOINTS OF TREATMENT**

## **11 VITILIGO - MARKETED PRODUCTS**

11.1 List of Vitiligo Marketed Drugs Across the Top 7 Markets

11.1.1 Opzelura (Ruxolitinib) - Incyte Corporation/Novartis



- 11.1.1.1 Drug Overview
- 11.1.1.2 Mechanism of Action
- 11.1.1.3 Regulatory Status
- 11.1.1.4 Clinical Trial Results
- 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## **12 VITILIGO - PIPELINE DRUGS**

### 12.1 List of Vitiligo Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Afamelanotide - Clinuvel Pharmaceuticals

- 12.1.1.1 Drug Overview
- 12.1.1.2 Mechanism of Action
- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status

#### 12.1.2 Ritlecitinib - Pfizer

- 12.1.2.1 Drug Overview
- 12.1.2.2 Mechanism of Action
- 12.1.2.3 Clinical Trial Results
- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status

#### 12.1.3 Upadacitinib - AbbVie

- 12.1.3.1 Drug Overview
- 12.1.3.2 Mechanism of Action
- 12.1.3.3 Clinical Trial Results
- 12.1.3.4 Safety and Efficacy
- 12.1.3.5 Regulatory Status

#### 12.1.4 Povorcitinib - Incyte Corporation

- 12.1.4.1 Drug Overview
- 12.1.4.2 Mechanism of Action
- 12.1.4.3 Clinical Trial Results
- 12.1.4.4 Safety and Efficacy
- 12.1.4.5 Regulatory Status

#### 12.1.5 AMG 714 - Amgen

- 12.1.5.1 Drug Overview
- 12.1.5.2 Mechanism of Action
- 12.1.5.3 Clinical Trial Results

12.1.5.4 Safety and Efficacy

12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. VITILIGO - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. VITILIGO – CLINICAL TRIAL LANDSCAPE**

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

## **15 VITILIGO - MARKET SCENARIO**

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Vitiligo - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Vitiligo - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Vitiligo - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Vitiligo - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Vitiligo - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Vitiligo - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Vitiligo - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

- 15.4.3 Vitiligo - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Vitiligo - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Vitiligo - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Vitiligo - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Vitiligo - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Vitiligo - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Vitiligo - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Vitiligo - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Vitiligo - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Vitiligo - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Vitiligo - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Vitiligo - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Vitiligo - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Vitiligo - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Vitiligo - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)  
15.9.3 Vitiligo - Access and Reimbursement Overview

## **16 VITILIGO - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 VITILIGO MARKET - SWOT ANALYSIS**

17.1 Strengths  
17.2 Weaknesses  
17.3 Opportunities  
17.4 Threats

## **18 VITILIGO MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Vitiligo Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/V664D49B9A64EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V664D49B9A64EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

